Serial Number | 90357299 |
Word Mark | EXO-TARGET |
Filing Date | Thursday, December 3, 2020 |
Status | 681 - PUBLICATION/ISSUE REVIEW COMPLETE |
Status Date | Thursday, October 17, 2024 |
Registration Number | 0000000 |
Registration Date | NOT AVAILABLE |
Mark Drawing | 4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
Published for Opposition Date | Tuesday, November 19, 2024 |
Goods and Services | Pharmaceutical preparations for treating cancer, metabolic disease, inflammatory disease, genetic disease, infectious diseases, cardiovascular disease, respiratory disease, neurological disease, auto-immune disease, fibrosis disease; chemico-pharmaceutical preparations for the treatment of cancer, metabolic disease, inflammatory disease, genetic disease, infectious diseases, cardiovascular disease, respiratory disease, neurological disease, auto-immune disease, fibrosis disease; drug delivery agents in the form of capsules, tablets, pills, powders, liquids, suspensions, injection, creams, emulsions, gels, liniments, lotions, ointments, pathes, solutions, syrups, aerosols, granules, implants, inhalants, pellets that facilitate the delivery of pharmaceutical preparations for the treatment of cancer, metabolic disease, inflammatory disease, genetic disease, infectious diseases, cardiovascular disease, respiratory disease, neurological disease, auto-immune disease, fibrosis disease; biological preparations in the nature of comprising extracellular vesicles known as exosomes for therapeutic applications; extracellular vesicles for pharmaceutical purposes for the treatment of cancer, metabolic disease, inflammatory disease, genetic disease, infectious diseases, cardiovascular disease, respiratory disease, neurological disease, auto-immune disease, fibrosis disease; biochemical drug delivery agent in the form of capsules, tablets, pills, powders, liquids, suspensions, injection, creams, emulsions, gels, liniments, lotions, ointments, pathes, solutions, syrups, aerosols, granules, implants, inhalants, pellets that facilitate the delivery of pharmaceutical preparations for the treatment of cancer, metabolic disease, inflammatory disease, genetic disease, infectious diseases, cardiovascular disease, respiratory disease, neurological disease, auto-immune disease, fibrosis disease; nutraceutical preparations for therapeutic or medical purposes for the treatment of cancer, metabolic disease, inflammatory disease, genetic disease, infectious diseases, cardiovascular disease, respiratory disease, neurological disease, auto-immune disease, fibrosis disease; chemical preparations for pharmaceutical purposes for the treatment of cancer, metabolic disease, inflammatory disease, genetic disease, infectious diseases, cardiovascular disease, respiratory disease, neurological disease, auto-immune disease, fibrosis disease; chemical preparations for medical purposes for the treatment of cancer, metabolic disease, inflammatory disease, genetic disease, infectious diseases, cardiovascular disease, respiratory disease, neurological disease, auto-immune disease, fibrosis disease; preparations of microorganisms for medical and veterinary use for the treatment of cancer, metabolic disease, inflammatory disease, genetic disease, infectious diseases, cardiovascular disease, respiratory disease, neurological disease, auto-immune disease, fibrosis disease; reagents for use in medical genetic testing; diagnostic reagents for medical use; biological preparations for medical or veterinary purposes for the treatment of cancer, metabolic disease, inflammatory disease, genetic disease, infectious diseases, cardiovascular disease, respiratory disease, neurological disease, auto-immune disease, fibrosis disease; biological reagents for clinical medical use |
Goods and Services | Biological preparations, other than for medical or veterinary purposes; biological tissue cultures, other than for medical or veterinary purposes; biological preparation for use in cell cultures other than for medical or veterinary use; biological preparation for use in the manufacture of pharmaceuticals; chemical additives for use in the manufacture of pharmaceuticals; chemical additives for use in the manufacture of cosmetics; protein for use in the manufacture of cosmetics; proteins for the food industry; chemical reagents, other than for medical or veterinary purpose |
Goods and Services | Biotechnology research; technological research in the field of cell biology; laboratory research in the field of cell biology; pharmaceutical drug development services; genetic testing for scientific research purposes; research in the field of chemistry; drug discovery services; medical research and development services; pharmaceutical research and development services; biopharmaceutical research and development services |
International Class | 001 - Chemicals used in industry, science and photography, as well as in agriculture, horticulture and forestry; unprocessed artificial resins; unprocessed plastics; manures; fire extinguishing compositions; tempering and soldering preparations; chemical substances for preserving foodstuffs; tanning substances; adhesives used in industry. |
US Class Codes | 001, 005, 006, 010, 026, 046 |
Class Status Code | 6 - Active |
Class Status Date | Tuesday, February 9, 2021 |
Primary Code | 001 |
First Use Anywhere Date | NOT AVAILABLE |
First Use In Commerce Date | NOT AVAILABLE |
International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
US Class Codes | 005, 006, 018, 044, 046, 051, 052 |
Class Status Code | 6 - Active |
Class Status Date | Tuesday, February 9, 2021 |
Primary Code | 005 |
First Use Anywhere Date | NOT AVAILABLE |
First Use In Commerce Date | NOT AVAILABLE |
International Class | 042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software. |
US Class Codes | 100, 101 |
Class Status Code | 6 - Active |
Class Status Date | Tuesday, February 9, 2021 |
Primary Code | 042 |
First Use Anywhere Date | NOT AVAILABLE |
First Use In Commerce Date | NOT AVAILABLE |
Party Name | ILIAS Biologics Inc. |
Party Type | 10 - Original Applicant |
Legal Entity Type | 03 - Corporation |
Address | Daejeon 34014 KR |
Event Date | Event Description |
Monday, December 7, 2020 | NEW APPLICATION ENTERED |
Thursday, June 3, 2021 | NON-FINAL ACTION E-MAILED |
Tuesday, February 9, 2021 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
Thursday, May 20, 2021 | ASSIGNED TO EXAMINER |
Thursday, June 3, 2021 | NON-FINAL ACTION WRITTEN |
Thursday, June 3, 2021 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
Friday, December 3, 2021 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
Friday, December 3, 2021 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
Saturday, December 4, 2021 | TEAS/EMAIL CORRESPONDENCE ENTERED |
Thursday, February 1, 2024 | SUSPENSION CHECKED - TO ATTORNEY FOR ACTION |
Wednesday, January 5, 2022 | LETTER OF SUSPENSION E-MAILED |
Wednesday, January 5, 2022 | NOTIFICATION OF LETTER OF SUSPENSION E-MAILED |
Wednesday, January 5, 2022 | SUSPENSION LETTER WRITTEN |
Monday, July 18, 2022 | SUSPENSION CHECKED - TO ATTORNEY FOR ACTION |
Wednesday, October 12, 2022 | REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED |
Tuesday, April 18, 2023 | SUSPENSION CHECKED - TO ATTORNEY FOR ACTION |
Thursday, July 6, 2023 | REPORT COMPLETED SUSPENSION CHECK CASE STILL SUSPENDED |
Monday, February 26, 2024 | SUSPENSION INQUIRY WRITTEN |
Monday, February 26, 2024 | INQUIRY TO SUSPENSION E-MAILED |
Monday, February 26, 2024 | NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED |
Sunday, May 26, 2024 | TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED |
Monday, June 24, 2024 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
Monday, June 24, 2024 | TEAS/EMAIL CORRESPONDENCE ENTERED |
Monday, June 24, 2024 | ASSIGNED TO LIE |
Monday, July 8, 2024 | FINAL REFUSAL E-MAILED |
Monday, July 8, 2024 | NOTIFICATION OF FINAL REFUSAL EMAILED |
Monday, July 8, 2024 | FINAL REFUSAL WRITTEN |
Monday, October 7, 2024 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
Monday, October 7, 2024 | TEAS/EMAIL CORRESPONDENCE ENTERED |
Monday, October 7, 2024 | TEAS REQUEST FOR RECONSIDERATION RECEIVED |
Friday, October 11, 2024 | APPROVED FOR PUB - PRINCIPAL REGISTER |